Clinical Trails
- International ,Randomised,open label, Phase 3 trial of Paclitaxel/ Carboplatin plus PF-3512676 Vs Pcli/Carbo alone as first line treatment of patients with advanced NSCLC.
- Randomised, controlled ,open labelled, Multicentre Comparison of THaliomide versus High – dose Dexamenthasone for the Treatment of Relapsed Refractory Multiple Myeloma.
- Randomised,Open Label, Multicenter,Phase 3 Study Of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Versus Standard Supportive Care In Anaemic Patients With Metastatic Breast Cancer Receiving First Line Standard Chemotherapy.
- A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCl in Patients with Advanced Multiple Myeloma.
- An Open- Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and/or Metastatic Breast Cancer.
- To study safety and efficacy of Recombinant Granulocyte-Colony Stimulating Factor, rG-CSF (ReliGrastTM) in patients with chemotherapy induces neutropenia.
|
|
